Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Bibliographic Details
Main Authors: Kefford, Richard, Sullivan, Ryan J, Miller, Wilson H, Elez, Elena M, Tan, Daniel, Kim, Kevin B, Long, Georgina V, Flaherty, Keith T, Tai, David, Stutvoet, Simone, Maacke, Heiko, Whiley, Matt, Parseval, Laure Moutouh-de, Tabernero, Josep
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108878/

Similar Items

Similar Items